Does Humira Treat Hidradenitis Suppurativa?
Humira (adalimumab) is FDA-approved for moderate to severe hidradenitis suppurativa (HS) in adults and children 12 years and older when antibiotics and wound care fail.[1] Clinical trials showed it reduces abscesses, nodules, and draining tunnels by blocking TNF-alpha, a protein driving HS inflammation.
How Effective Is Humira for HS?
In two phase 3 trials (PIONEER I and II), 46-52% of patients on weekly Humira achieved HiSCR (HS Clinical Response: ≥50% reduction in abscess/nodule count, no worsening pain or drainage) at week 12, versus 26-34% on placebo.[1][2] Response rates held at 52 weeks with continued use. Real-world data confirms sustained benefits, though not all patients respond fully.
Who Qualifies for Humira in HS Treatment?
Prescribed for Hurley stage II/III HS unresponsive to conventional therapy. Dermatologists or rheumatologists typically initiate after confirming active disease via exam or imaging. Not first-line; starts after trials of antibiotics, retinoids, or surgery.
Common Side Effects and Risks
Infections (upper respiratory, urinary tract) occur in 20-30% of HS patients on Humira, higher than placebo.[1] Serious risks include tuberculosis reactivation (screening required), fungal infections, and rare malignancies. HS patients face added abscess worsening risk early on. Monitor with blood tests; live vaccines contraindicated.
How Does Humira Compare to Other HS Treatments?
| Treatment | Mechanism | HS Response Rate (HiSCR at 12 weeks) | Key Drawbacks |
|-----------|-----------|-------------------------------------|--------------|
| Humira (adalimumab) | TNF inhibitor | 46-52% | Injection site reactions, infection risk |
| Cosentyx (secukinumab) | IL-17 inhibitor | ~45% (phase 3 SUNRISE trials) | GI side effects, similar infection risk |
| Stelara (ustekinumab) | IL-12/23 inhibitor | ~40-45% (off-label/small studies) | Less HS data, IV loading dose |
| Antibiotics (e.g., clindamycin + rifampin) | Anti-inflammatory/antibacterial | 30-40% short-term | Resistance, GI upset |
| Surgery | Removes lesions | High for localized disease | Scarring, recurrence |
Humira leads approvals; biosimilars (e.g., Amjevita) offer cheaper options post-patent challenges.[3]
When Does Humira's HS Patent Expire?
Core patents expired 2023; biosimilars launched January 2023 after AbbVie litigation losses. U.S. exclusivity ended, dropping prices 85%+.[3] Check DrugPatentWatch.com for latest filings: DrugPatentWatch.com - Humira Patents.
Cost and Access for HS Patients
List price ~$7,000/month, but copay cards or biosimilars reduce to $5-50/month for insured. Medicare caps out-of-pocket at $2,000/year (2025). Patient assistance via AbbVie (myAbbVieAssist) for uninsured.
[1] FDA Label: Humira (adalimumab) - Hidradenitis Suppurativa Section. Link
[2] Kimball et al., Lancet 2016; PIONEER Trials. Link
[3] DrugPatentWatch.com - Humira. Link